Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Xo Biologix
EIR
•Xo Biologix•January 5, 2024

Xo Biologix – FDA EIR, Jan 5, 2024

Record Details

An FDA inspection of Xo Biologix, a distributor of human tissue products, was conducted from January 3-5, 2024, in Austin, TX. This initial inspection, performed under regulatory guidelines for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), aimed to assess the firm's operations. While no formal inspectional observations (FDA 483) were issued, three significant issues were identified through discussions with management.

Firstly, the firm's FDA registration was inaccurate, failing to reflect its correct legal name, current contact information, and the specific tissue products it was distributing. Secondly, the Supplier Quality Agreement between Xo Biologix and its contract manufacturer lacked clarity regarding each party's responsibilities, particularly concerning the Instructions for Use for the MaviX product. Finally, the company was receiving Tissue Usage Records (TURs) but not actively reviewing them. This oversight led to the discovery of widespread off-label use of the MaviX product by practitioners, for purposes beyond its intended topical wound care application, including internal and injectable routes.

In response, Xo Biologix committed to promptly updating its FDA registration and revising its supplier agreement to clearly delineate responsibilities. Furthermore, management indicated they would begin reviewing TURs, communicate with distributors about the intended use of MaviX, and consider discontinuing sales to individuals or practices misusing the product.

Company
Xo Biologix
Inspection date
January 5, 2024
Product type
Biologics
Office
Office of Biological Products Operations - Division II
People
  • Bobbi Miller
  • Richard T. Riggie (investigator)
  • Rachel Fulk (company_representative)
  • David P. Janice (recipient)
View Company Profile

ID · 88a486ab-e536-4664-a78c-8d76f3174bf9

Other documents for Xo Biologix
  • WARNING_LETTER - 2024-01-05January 5, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Xo Biologix
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.